Loading
A phase 3 trial testing GQ1005 in HER2-positive breast cancer, now recruiting.
A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer is a phase 3 interventional study registered as NCT07673029, led by GeneQuantum Healthcare (Suzhou), and recruiting on the registry. Official title: A Phase III, Multicenter, Open-label, Randomised Controlled Study Comparing GQ1005 and Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and a Taxane. Planned enrolment is 228 participants (estimated). The study started in 2025-01-10 and primary completion is expected in 2027-01-09. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/